TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

SEYSARA

SARECYCLINE HYDROCHLORIDE
Immunology Approved 2018-10-01
1
Indication
--
Phase 3 Trials
7
Years on Market

Details

Status
Prescription
First Approved
2018-10-01
Routes
ORAL
Dosage Forms
TABLET

Companies

Active Ingredient: SARECYCLINE HYDROCHLORIDE

SEYSARA Approval History

Loading approval history...

What SEYSARA Treats

1 indications

SEYSARA is approved for 1 conditions since its original approval in 2018. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Acne Vulgaris
Source: FDA Label

Drugs Similar to SEYSARA

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

ACANYA
BENZOYL PEROXIDE
1 shared
BAUSCH
Shared indications:
Acne Vulgaris
ACZONE
DAPSONE
1 shared
ALMIRALL
Shared indications:
Acne Vulgaris
ADAPALENE AND BENZOYL PEROXIDE
ADAPALENE
1 shared
PADAGIS ISRAEL
Shared indications:
Acne Vulgaris
AKLIEF
TRIFAROTENE
1 shared
GALDERMA LABS LP
Shared indications:
Acne Vulgaris
ALTRENO
TRETINOIN
1 shared
DOW PHARM
Shared indications:
Acne Vulgaris
AMZEEQ
MINOCYCLINE HYDROCHLORIDE
1 shared
JOURNEY
Shared indications:
Acne Vulgaris
ARAZLO
TAZAROTENE
1 shared
BAUSCH
Shared indications:
Acne Vulgaris
ATRALIN
TRETINOIN
1 shared
DOW PHARM
Shared indications:
Acne Vulgaris
AVAGE
TAZAROTENE
1 shared
ALMIRALL
Shared indications:
Acne Vulgaris
AZELEX
AZELAIC ACID
1 shared
ALMIRALL
Shared indications:
Acne Vulgaris
BENZAMYCIN
BENZOYL PEROXIDE
1 shared
VALEANT INTL
Shared indications:
Acne Vulgaris
CABTREO
ADAPALENE
1 shared
BAUSCH
Shared indications:
Acne Vulgaris
CLEOCIN T
CLINDAMYCIN PHOSPHATE
1 shared
Pfizer
Shared indications:
Acne Vulgaris
CLINDA-DERM
CLINDAMYCIN PHOSPHATE
1 shared
PADAGIS US
Shared indications:
Acne Vulgaris
CLINDAGEL
CLINDAMYCIN PHOSPHATE
1 shared
BAUSCH
Shared indications:
Acne Vulgaris
CLINDAMYCIN PHOSPHATE
CLINDAMYCIN PHOSPHATE
1 shared
TARO
Shared indications:
Acne Vulgaris
CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE
BENZOYL PEROXIDE
1 shared
Teva
Shared indications:
Acne Vulgaris
CLINDAMYCIN PHOSPHATE AND TRETINOIN
CLINDAMYCIN PHOSPHATE
1 shared
SOLARIS PHARMA CORP
Shared indications:
Acne Vulgaris
CLINDAMYCIN PHOSPHATE IN 0.9% SODIUM CHLORIDE
CLINDAMYCIN PHOSPHATE
1 shared
Baxter
Shared indications:
Acne Vulgaris
CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER
CLINDAMYCIN PHOSPHATE
1 shared
RISING
Shared indications:
Acne Vulgaris
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

SEYSARA FDA Label Details

Pro

Indications & Usage

FDA Label (PDF)

SEYSARA ® (sarecycline) tablet, is indicated for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 9 years of age and older. Limitations of Use Efficacy of SEYSARA beyond 12 weeks and safety beyond 12 months have not been established. SEYSARA has not been evaluated in the treatment of infections [see Clinical Studies ] . To reduce the development of drug-resistant bacteria as well as to maintain the effectiveness of other antibacterial drugs, SEYSARA should be used only as indicated [see Warnings and Precautions ] . SEYSARA ® is a tetracycline-cl...

SEYSARA Patents & Exclusivity

Latest Patent: Feb 2033

Patents (45 active)

US9255068 Expires Feb 9, 2033
US8318706 Expires Jan 3, 2032
US8513223 Expires Dec 7, 2029
US9481639 Expires Aug 10, 2028
+ 35 more patents
Source: FDA Orange Book

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.